Quantcast

Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
Welcome, Guest. Please login or register.
July 29, 2014, 01:58:37 PM

Login with username, password and session length


Members
Stats
  • Total Posts: 632270
  • Total Topics: 47877
  • Online Today: 259
  • Online Ever: 585
  • (January 07, 2014, 02:31:47 PM)
Users Online

Welcome


Welcome to the POZ/AIDSmeds Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ/AIDSmeds community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: When will Raltegravir be available for fist timers?  (Read 1225 times)

0 Members and 1 Guest are viewing this topic.

Offline Miss Philicia

  • Member
  • Posts: 23,899
  • celebrity poster, faker & poser
When will Raltegravir be available for fist timers?
« on: January 10, 2008, 09:17:52 AM »
the following if from the Poz Health Digest that I receive daily via email and may be of interest to those of you that are treatment naive, though I would assume that you'd need a more "progressive" HIV specialist to agree to go this route.  Personally I would consider it if it was me making this decision.  I believe if you wish to receive these bulletins you can send an email to: mailto:PozHealth@yahoogroups.com

ps:  Raltegravir is the same as Isentress, which is what I began 2 months ago -- seriously, it has NO side effects that I can tell.  Amazing and strong med.

When will Raltegravir be available for fist timers?
Posted by: "Jason Thomas" malebeyo@yahoo.com   malebeyo
Wed Jan 9, 2008 6:42 am (PST)

It looks like there already is 48 week data on it in treatment naive.
Is anyone here currently taking Raltegravir and what have been your
experiences with side effects and effectiveness of this med?

The integrase inhibitor raltegravir has impressive activity in
treatment-experienced patients (ACC May 7 2007) and, according to a
24-week analysis, may have similarly potent effects in patients who
are treatment naive (ACC Sep 18 2006). Now, 48-week results are
available from this same industry-sponsored study.

The trial involved 201 treatment-naive patients, including 30 who
participated in an initial 10-day study of raltegravir monotherapy (J
Acquir Immune Defic Syndr 2006; 43:509). All were randomized to
receive tenofovir and 3TC, plus either efavirenz or one of four doses
of raltegravir (100 mg, 200 mg, 400 mg, or 600 mg twice daily). Entry
criteria included a viral load ≥5000 copies/mL and a CD4 count ≥100
cells/mm3. At baseline, the mean viral load ranged across treatment
arms from 4.6 to 4.8 log copies/mL, and the mean CD4 count ranged from
271 to 338 cells/mm3.

By week 48, approximately 85% of patients in each group had achieved
viral loads <50 copies/mL. Viral loads became undetectable more
rapidly in patients who received raltegravir at any dose than in those
who received efavirenz (P<0.05). CD4-cell responses were similar among
treatment arms. Central nervous system side effects and lipid
elevations occurred more commonly in those who received efavirenz.
Virologic failure occurred in 3% of patients in each group; of the
five raltegravir recipients who experienced virologic failure, two had
viruses with the N155H amino acid substitution, a mutation known from
in vitro experiments to be selected by raltegravir.
Comment

These 48-week results confirm that raltegravir is likely to be at
least as potent as efavirenz when used in an initial regimen with two
NRTIs. The clinical relevance of the faster decline in viral load is
unclear, but the observation is certainly remarkable given that
efavirenz-based regimens induce a faster HIV RNA decline than do
regimens using boosted PIs. Although the authors speculate that
patients with raltegravir resistance might have maintained viral loads
below baseline because of a reduction in viral fitness due to
raltegravir-selected mutations, this phenomenon has previously been
well described with NRTI resistance, which was also present in these
patients. Given these impressive results overall, we eagerly
anticipate the findings of a larger, phase III study of raltegravir
versus efavirenz that is already fully enrolled. If that study yields
similarly favorable results, the decision about when to consider
raltegravir a first-line therapy option will be up to individual
clinicians, patients, and various guidelines committees, with the
major concern being the absence of long-term safety data.
« Last Edit: January 10, 2008, 09:20:18 AM by philly267 »
"Iíve slept with enough men to know that Iím not gay"

Offline aztecan

  • Member
  • Posts: 5,384
  • 29 years positive, 56 years a pain in the butt
Re: When will Raltegravir be available for fist timers?
« Reply #1 on: January 11, 2008, 09:04:19 AM »
Oh, sorry, I read the thread title and thought you were getting kinky. ;)

It was an interesting piece, though.

HUGS,

Mark
"May your life preach more loudly than your lips."
~ William Ellery Channing (Unitarian Minister)

Offline allopathicholistic

  • Member
  • Posts: 3,258
Re: When will Raltegravir be available for fist timers?
« Reply #2 on: January 11, 2008, 10:06:46 AM »
My doctor said he would prescribe Raltegravir if someone was having bad nausea from Lexiva and was okay with a twice-a-day regimen. Other than that he didnt say much else.

 


Terms of Membership for these forums
 

© 2014 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.